Skip to main content

Advertisement

Log in

Acute Myeloid Leukemia After Treatment of Early Breast Cancer: Case Report and Literature Review

  • Case Report
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Background

Therapy-related acute myeloid leukemia has been widely accepted for decades as one of the most serious long-term complications of treatment for early breast cancer.

Case

We report the case of a patient with therapy-related acute myeloid leukemia that may have been caused by regional radiation, chemotherapy, or endocrine therapy after surgery. A 35-year-old female was diagnosed 7 years ago as having stage IIA left breast cancer; she was treated by conservative surgery, followed by chemotherapy, radiotherapy, and endocrine therapy for 5 years. After 1 year of active follow-up, she presented with complaints of mild fever, weakness, loss of appetite, weight loss, and multiple bruises all over the body. Complete blood count revealed a hemoglobin level of 4 g/dl and total leukocyte count of 40,000 cells/mm3, with multiple blast cells in peripheral smear. Bone marrow biopsy and immunophenotyping established the diagnosis as AML. Before starting the treatment, she died following multiple organ failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641.

    Article  Google Scholar 

  2. Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26:1239.

    Article  Google Scholar 

  3. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol. 2003;30:740.

    Article  CAS  Google Scholar 

  4. Rubagotti A, Perrotta A, Casella C, Boccardo F. Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. Ann Oncol. 1996;7:239.

    Article  CAS  Google Scholar 

  5. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematol Am Soc Hematol Educ Progr. 2007;2007:453–9.

    Article  Google Scholar 

  6. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003;21:1195–204.

    Article  CAS  Google Scholar 

  7. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418–29.

    Article  CAS  Google Scholar 

  8. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205.

    Article  CAS  Google Scholar 

  9. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292–300.

    Article  Google Scholar 

  10. Ono M, Watanabe T, Shimizu C, Hiramoto N, Goto Y, Yonemori K, Kouno T, Ando M, Tamura K, Katsumata N, Fujiwara Y. Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. Jpn J Clin Oncol. 2008;38(8):567–70. https://doi.org/10.1093/jjco/hyn057.

    Article  PubMed  Google Scholar 

  11. Yalcin S, Gullu I, Demiroglu H, Tekuzman G. Acute leukemia during tamoxifen therapy. Med Oncol. 1997;14:61–2.

    Article  CAS  Google Scholar 

  12. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 1995;87:645–51.

    Article  CAS  Google Scholar 

  13. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.

    Article  Google Scholar 

  14. Haas JF, Kittelmann B, Mehnert WH, Staneczek W, Mohner M, Kaldor JM, et al. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987;55:213–8.

    Article  CAS  Google Scholar 

  15. Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett JM, editor. The myelodysplastic syndromes: pathobiology and clinical management. New York: Marcel Dekker, Inc.; 2002. p. 139–76.

    Google Scholar 

  16. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–85.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Special thanks are due to the Faculty of Medicine and Pharmacy of Marrakech and Cadi Ayyad University of Marrakech.

Author information

Authors and Affiliations

Authors

Contributions

IL and IE performed the research and wrote the manuscript. RB, AE, and MK coordinated the research and revised and approved the final manuscript.

Corresponding author

Correspondence to Issam Lalya.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lalya, I., Essadi, I., Belbaraka, R. et al. Acute Myeloid Leukemia After Treatment of Early Breast Cancer: Case Report and Literature Review. Indian J Gynecol Oncolog 17, 60 (2019). https://doi.org/10.1007/s40944-019-0308-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-019-0308-z

Keywords

Navigation